2026-06-14T10:37:40Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/263312025-12-18T13:00:06Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19608
00925njm 22002777a 4500
dc
Pastor-Barriuso, Roberto
author
Nuñez, Olivier
author
Monge Corella, Susana
author
Nirsevimab Effectiveness Study Collaborators
author
Jarrin Vera, Inmaculada
author
2025
Pastor-Barriuso Roberto, Núñez Olivier, Monge Susana, the Nirsevimab Effectiveness Study Collaborators. Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season. Euro Surveill. 2025;30(6):2500040.
10.2807/1560-7917.ES.2025.30.6.2500040
1560-7917
1025-496X
Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin
https://hdl.handle.net/20.500.12105/26331
Infant
Nirsevimab
Effectiveness
Hospitalisation
Respiratory syncytial virus
Immunise
Spain
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season